PI3K inhibitors in thrombosis and cardiovascular disease

被引:65
|
作者
Durrant, Tom N. [1 ]
Hers, Ingeborg [2 ]
机构
[1] Univ Oxford, Dept Chem, Oxford OX1 3QZ, England
[2] Sch Physiol Pharmacol & Neurosci, Biomed Sci Bldg,Univ Walk, Bristol BS8 1TD, Avon, England
来源
CLINICAL AND TRANSLATIONAL MEDICINE | 2020年 / 9卷 / 01期
关键词
Cardiovascular disease; Thrombosis; Platelets; Phosphoinositide; 3-kinase; PI3K; Phosphoinositides; Cellular signalling; II PHOSPHOINOSITIDE 3-KINASE; REGULATES PLATELET ACTIVATION; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; PI3K-GAMMA INHIBITION; P110-ALPHA ISOFORM; P110-BETA SUBUNIT; CRYSTAL-STRUCTURE; P2Y(12) RECEPTOR; DOSE-ESCALATION; CELL-MIGRATION;
D O I
10.1186/s40169-020-0261-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that regulate important intracellular signalling and vesicle trafficking events via the generation of 3-phosphoinositides. Comprising eight core isoforms across three classes, the PI3K family displays broad expression and function throughout mammalian tissues, and the (patho)physiological roles of these enzymes in the cardiovascular system present the PI3Ks as potential therapeutic targets in settings such as thrombosis, atherosclerosis and heart failure. This review will discuss the PI3K enzymes and their roles in cardiovascular physiology and disease, with a particular focus on platelet function and thrombosis. The current progress and future potential of targeting the PI3K enzymes for therapeutic benefit in cardiovascular disease will be considered, while the challenges of developing drugs against these master cellular regulators will be discussed.
引用
收藏
页数:21
相关论文
共 50 条
  • [1] PI3K Inhibitors in Cardiovascular Disease
    Eisenreich, Andreas
    Rauch, Ursula
    CARDIOVASCULAR THERAPEUTICS, 2011, 29 (01) : 29 - 36
  • [2] PI3K and Calcium Signaling in Cardiovascular Disease
    Ghigo, Alessandra
    Laffargue, Muriel
    Li, Mingchuan
    Hirsch, Emilio
    CIRCULATION RESEARCH, 2017, 121 (03) : 282 - 292
  • [3] Isoform-Selective PI3K Inhibitors for Various Diseases
    Bheemanaboina, Rammohan R. Y.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2020, 20 (12) : 1074 - 1092
  • [4] Development of single and mixed isoform selectivity PI3Kδ inhibitors by targeting Asn836 of PI3Kδ
    Miller, Michelle S.
    Mountford, Simon J.
    Pinson, Jo-Anne
    Zheng, Zhaohua
    Kunzli, Marco
    Patel, Vanit
    Hogg, Simon J.
    Shortt, Jake
    Jennings, Ian G.
    Thompson, Philip E.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (19) : 4790 - 4794
  • [5] Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma
    Westin, Jason R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05) : 335 - 342
  • [6] Potential role of PI3K inhibitors in the treatment of breast cancer
    Carvalho, Silvia
    Schmitt, Fernando
    FUTURE ONCOLOGY, 2010, 6 (08) : 1251 - 1263
  • [7] Development of PI3Kα inhibitors for tumor therapy
    Jia, Wenqing
    Luo, Shuyu
    Guo, Han
    Kong, Dexin
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (17) : 8587 - 8604
  • [8] PI3K Inhibitors as Novel Cancer Therapies: Implications for Cardiovascular Medicine
    Mclean, Brent A.
    Zhabyeyev, Pavel
    Pituskin, Edith
    Paterson, Ian
    Haykowsky, Mark J.
    Oudit, Gavin Y.
    JOURNAL OF CARDIAC FAILURE, 2013, 19 (04) : 268 - 282
  • [9] Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
    Rewcastle, Gordon W.
    Kolekar, Sharada
    Buchanan, Christina M.
    Gamage, Swarna A.
    Giddens, Anna C.
    Tsang, Kit Y.
    Kendall, Jackie D.
    Singh, Ripudaman
    Lee, Woo-Jeong
    Smith, Greg C.
    Han, Weiping
    Matthews, David J.
    Denny, William A.
    Shepherd, Peter R.
    Jamieson, Stephen M. F.
    ONCOTARGET, 2017, 8 (29) : 47725 - 47740
  • [10] Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
    Tarantelli, Chiara
    Lupia, Antonio
    Stathis, Anastasios
    Bertoni, Francesco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (03)